Sponsored by

Seven takeaways from Tony Coles' closing comments at MassBio's meeting

In a fireside chat to close the group's annual meeting, Coles focused on themes of drug pricing, criticism of the industry, and whether he would want to run for public office.

The world’s leading immigration law firm, right here in Boston. See how your view of the world changes when you work with a firm totally focused on immigration.

​Gilead’s $1.2B deal is just the latest between tiny Nimbus and a biotech giant

One question the company is sure to get is why it just sell the whole company, rather than it’s lead — and only disclosed — drug in development?

AstraZeneca spinout Entasis gets $50M for antibiotic resistant infection drugs

​Waltham-based Entasis Therapeutics, which is focused on treating antibiotic-resistant bacterial infections, has secured $50 million to progress its pipeline of drugs.

GE to donate tens of millions to Boston schools, health care centers

The donations, which will take place over five years, will focus heavily on workforce development.

​Boston Scientific reports pay for top Minnesota executive

Slowdown in startupland: A pause, a pop or new normal?